Article
Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation
19 Apr 2016
Abstract excerpt
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for hematologic malignancies and non-malignant diseases. Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase. However, allo-HSCT is still limited by complications, such as graft-versus-host disease (GVHD), which is associated with important morbidity and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
